Artificial intelligence has a talent for making us feel simultaneously futuristic and slightly irresponsible. You can deploy an AI assistant that drafts customer emails in six languages, summarizes incident reports, and writes Terraform that mostly works on the first try. And then—because we can’t have nice things—it also opens up new ways to leak data,…
AI Health Tools Are Everywhere. Do They Actually Work? Evidence, Regulation, and the Reality Check Healthcare Needs
AI in healthcare has entered its “there’s an app for that” era—except now it’s “there’s a model for that,” and it may be embedded in your radiology workflow, your insurer’s prior-auth portal, your clinician’s documentation tools, and your phone’s symptom checker. The trouble is that availability is not the same thing as effectiveness. In other…
AI insurance underwriting is past the pitch deck: Gradient AI lands CIBC growth capital—and the insurtech ‘scale test’ begins
AI-powered insurance underwriting has spent the last decade living a double life: dazzling conference demos on one hand, and quietly bumping into legacy policy systems (and grumpy regulators) on the other. This week, that tension got a little more interesting. On March 3, 2026, CIBC Innovation Banking announced it has provided growth capital financing to…
Is the Pentagon Allowed to Surveil Americans With AI? The Legal Loopholes, Data Broker Problem, and What Comes Next
AI is doing to surveillance what SSDs did to hard drives: it’s making something that used to be slow, noisy, and expensive suddenly fast, quiet, and—crucially—cheap enough to do at scale. That’s why the question posed by MIT Technology Review—“Is the Pentagon allowed to surveil Americans with AI?”—isn’t academic. It’s the kind of question that…
AI Agents Are Connecting to Everything — and Nobody’s Governing Them: Why Agent Governance Became the Hottest (and Messiest) New Control Plane
Somewhere in your infrastructure, an AI agent is running that nobody formally authorized. That line from Giant Swarm’s Dominik Schmidle is funny in the way smoke alarms are funny: it’s a clever sentence that also implies you may soon be explaining yourself to your CISO, your auditor, and that one engineer who still prints Jira…
Scaling Intelligent Automation Without Breaking Live Workflows: Elastic Architecture, Governance, and Agentic AI Done Right
Somewhere in every enterprise, an automation engineer is staring at a dashboard that looks calm—too calm—while the business is one unexpected demand spike away from discovering that its “scaled” automation is really just a large collection of fragile scripts wearing a trench coat. That tension—between ambition and operational reality—sits at the heart of a recent…
From the Endpoint to the Prompt: Cloudflare One’s Unified Data Security Vision (and Why It Matters Now)
Enterprise security has always had a flair for reinvention. We rename the perimeter every few years, move the “center” of the network to wherever the most expensive incidents happen, and then we buy tools to match the new diagram. In 2026, the diagram has a new box labeled “AI prompts”—and it’s connected to everything. Cloudflare…
Gemini Live Agent Challenge: Google Cloud’s $80K Push for Real‑Time Multimodal AI (and What Devs Should Actually Build)
Google Cloud has a message for developers on March 7, 2026: stop typing, start talking, and ideally let your app “see” what you mean while you’re at it. In a new post on the Google Cloud Blog, Dilasha Panigrahi (Product Marketing Manager) announced the Gemini Live Agent Challenge, a Devpost-hosted hackathon aimed squarely at building…
Google Workspace CLI: The Command Line Is Back, and This Time It’s Bringing AI Agents to Gmail, Docs, and Sheets
Somewhere, a veteran sysadmin just felt a strange tingling sensation: the command line is cool again. On March 6, 2026, VentureBeat’s Carl Franzen reported on a new Google Workspace CLI that pulls Gmail, Google Drive, Calendar, Docs, Sheets, Chat, Admin, and “every Workspace API” into a single terminal-first interface designed for both humans and AI…
Converge Bio’s $25M Series A Is a Vote for “GenAI Labs” in Drug Discovery (and a Warning About Hallucinating Molecules)
On January 13, 2026, TechCrunch reported that Converge Bio, an AI drug-discovery startup with operations spanning Boston and Tel Aviv, raised $25 million in a Series A round. The round was led by Bessemer Venture Partners, with participation from TLV Partners, Saras Capital, and Vintage Investment Partners, plus backing from unnamed executives affiliated with Meta,…